Skip to main content

Table 3 Utilization of medical care by participants with migraine (N = 3466)

From: Poor medical care for people with migraine in Europe – evidence from the Eurolight study

Country N Using triptans (of all with migraine) n (%) Migraine on ≥5 days/month n (%) Using preventative medication (of those with migraine on ≥5 days/month) n (%) Consulting health professionals n (%)
Specialist General practitioner Non-medical None
Studies with a general-population basis
Germany 109 12 (11.0) 42 (38.5) 1 (2.4) 7 (6.4) 14 (12.8) 5 (4.6) 83 (76.1)
Italy 221 14 (6.3) 61 (27.6) 1 (1.6) 14 (6.3) 21 (9.5) 15 (6.8) 171 (77.4)
Lithuania 149 5 (3.4) 62 (41.6) 2 (3.2) 16 (10.7) 23 (15.4) 2 (1.3) 108 (72.5)
Luxemburg 669 48 (7.2) 219 (32.7) 10 (4.6) 39 (5.8) 105 (15.7) 27 (4.0) 498 (74.4)
Netherlands-population 815 75 (9.2) 171 (20.8) 11 (6.4) 25 (3.1) 106 (13.0) 36 (4.4) 648 (79.5)
Spain-workplace 401 90 (22.4) 153 (38.2) 21 (13.7) 60 (15.0) 72 (18.0) 28 (7.0) 241 (60.1)
Studies conducted in general practice settings
Austria 263 37 (14.1) 106 (40.3) 7 (6.6) 46 (17.5) 26 (10.0) 14 (5.3) 177 (67.3)
France 337 46 (13.6) 91 (27.0) 4 (4.4) 7 (2.1) 81 (24.0) 22 (6.5) 227 (67.3)
UK 49 12 (24.5) 22 (44.9) 2 (9.1) 11 (22.4) 7 (14.3) 0 (0) 31 (63.3)
Studies among members of lay headache organizations
Ireland 152 94 (61.8) 78 (51.3) 23 (29.5) 34 (22.4) 45 (29.6) 6 (3.9) 67 (44.1)
Netherlands-lay 195 133 (68.2) 120 (61.5) 50 (41.7) 66 (33.8) 26 (13.3) 21 (11.0) 82 (42.1)
Spain-lay 106 49 (46.2) 50 (47.2) 8 (16.0) 25 (23.6) 27 (25.5) 10 (9.4) 44 (41.5)